The hammer and nail phenomenon: The expanding acceptance of active surveillance in urologic oncology

Klotz, 2018, The future of active surveillance, Transl. Androl Urol, 7, 256, 10.21037/tau.2018.01.12 Klotz, 2019, Contemporary approach to active surveillance for favorable risk prostate cancer, Asian J. Urol., 6, 146, 10.1016/j.ajur.2018.12.003 Giri, 2020, Implementation of germline testing for prostate cancer. Philadelphia Prostate Cancer Consensus Conference 2019, J. Clin. Oncol., 38, 2798, 10.1200/JCO.20.00046 Margel, 2012, Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study, J. Urol, 187, 1247, 10.1016/j.juro.2011.11.112 Turkbey, 2013, Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?, Radiology, 268, 144, 10.1148/radiol.13121325 Choo, 2002, Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, and histological and or clinical progression, J. Urol., 167, 1664, 10.1016/S0022-5347(05)65174-9 Klotz, 2003, Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer, Clin. Prost. Cancer, 2, 106, 10.3816/CGC.2003.n.017 Parker, 2003, Active surveillance: an individualized approach to early prostate cancer, BJU. Int., 92, 2, 10.1046/j.1464-410X.2003.04295.x Mahal, 2019, Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States 2010-2015, JAMA, 321, 704, 10.1001/jama.2018.19941 White, 2019, A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer, Cancer, 125, 952, 10.1002/cncr.31884 Mohler, 2019, Prostate cancer, version 2.2019, NCCN clinical practice guideline in oncology, J. Natl. Comp. Netw., 17, 479, 10.6004/jnccn.2019.0023 Lin, 2020, Genomic Prostate Score (GPS) results in The Canary Prostate Active Surveillance (PASS) cohort, J. Clin. Oncol., 38, 1549, 10.1200/JCO.19.02267 Pierorazio, 2012, Active surveillance for small renal masses, Rev.Urol, 14, 13 2010 Gulko C, Leapman M. Active Surveillance in Patients With Small Renal Masses.https://www.medpagetoday.com/resource-centers/gi-cancer/active-surveillance-patients. Accessed January 6, 2020. Ray, 2020, Active surveillance for small renal masses, Rev. Urol., 22, 9 Campbell, 2016, Malignant renal tumors, 1314 Johnson, 2015, Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series in the United States population level burden estimate, J. Urol, 193, 30, 10.1016/j.juro.2014.07.102 Smaldone, 2012, Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis, Cancer, 118, 997, 10.1002/cncr.26369 2017 Uzosikee, 2018, Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry, J. Urol., 641, 10.1016/j.juro.2017.09.087 Jewett, 2011, Active surveillance of small renal masses: progression patterns of early stage kidney cancer, Eur. Urol., 60, 39, 10.1016/j.eururo.2011.03.030 Smaldone MC. 2012, op. cit. Punnen, 2006, Variability in size measurement of renal masses smaller than 4 cm on computerized topography, J. Urol., 176, 2386, 10.1016/j.juro.2006.07.142 Patel, 2016, Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature, J. Urol., 195, 1340, 10.1016/j.juro.2015.11.029 Tomaszewski, 2014, Heterogeneity and renal mass biopsy – a review of its role and reliability, Cancer Biol. Med, 11, 162 Veltri, 2011, Diagnostic accuracy and clinical impact of imaging – guide needle biopsy of renal masses. Retrospective analysis on 150 cases, Eur. Radiol., 21, 393, 10.1007/s00330-010-1938-9 Pierorazio, 2015, Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry, Eur. Urol., 68, 408, 10.1016/j.eururo.2015.02.001 Chandrasekar, 2018, Natural history of complex renal cysts: clinical evidence supporting active surveillance, J. Urol., 199, 633, 10.1016/j.juro.2017.09.078 Flaig, 2020, Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw., 18, 329, 10.6004/jnccn.2020.0011 Burger, 2013, Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data, Eur Urol, 64, 846, 10.1016/j.eururo.2013.03.059 Xiong, 2017, A meta-analysis of narrow-band imaging for the diagnosis and therapeutic outcome of non-muscle invasive cancer, PLoS One, 12, 10.1371/journal.pone.0170819 Bosschieter, 2018, Value of an immediate instillation of mitomycin in C in protocols with non-muscle invasive bladder cancer: a prospective multicenter randomized study in 2243 patients, Eur Urol, 73, 226, 10.1016/j.eururo.2017.06.038 Solsona, 1999, Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up, J. Urol., 161, 1120, 10.1016/S0022-5347(01)61606-9 Tiu, 2014, Active surveillance for low-risk bladder cancer, Urol. Oncol., 32, 10.1016/j.urolonc.2012.12.003 Lakeshwar, 2001, Current bladder tumor tests: does their projected utility fulfill clinical necessity, J. Urol., 165, 1067, 10.1016/S0022-5347(05)66428-2 Darwizhe, 2015, Biomarkers for muscle invasive bladder cancer: current tests and future promise, Indian J. Urol., 31, 273, 10.4103/0970-1591.166448 Nagata, 2016, Molecular biomarkers in bladder cancer: novel potential indicators of prognosis and treatment outcomes, Disease Markers, 10.1155/2016/8205836 Billery, 2001, Frequent RGFRs mutations in papillary non-invasive bladder (pTa) tumors, Amer. J. Path., 158, 1955, 10.1016/S0002-9440(10)64665-2 van Rhijn, 2001, The fibroblast growth factor 3(FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate, Cancer Res, 61, 1265 Hurle, 2018, Pathologic outcomes for patients who failed to remain under active surveillance for low-risk, non-muscle-invasive bladder cancer: update and results from the bladder cancer Italian Active Surveillance, Eur. Urol. Oncol., 1, 437, 10.1016/j.euo.2018.05.006 Schulam, 2018 Peckham, 1979, Orchiectomy alone in testicular stage 1 non-seminomatous germ-cell tumors, Lancet, 2, 678 Sogani, 1984, Orchiectomy alone in the treatment of clinical stage 1 non-seminomatous germ cell tumors of the testis, J. Clin. Oncol., 2, 267, 10.1200/JCO.1984.2.4.267 Rhaghavan, 2000, Active Surveillance’ for stage 1 testis cancer: attaining maturity out 21 years, Eur. J. Cancer., 36, 1891, 10.1016/S0959-8049(00)00163-5 Kollmannsberger, 2015, Patterns of relapse in patients with clinical stage 1 testicular cancer managed with active surveillance, J. Clin. Oncol., 33, 51, 10.1200/JCO.2014.56.2116 Albers, 2011 Wood, 2010, Canadian consensus guidelines for the management of testicular germ cell cancer, Can. Urol. Assoc J., 4, e19, 10.5489/cuaj.815 Jeldres, 2014, United States trends in patterns of care in clinical stage 1 testicular cancer: results from the National Cancer Database (1998-2011), Clin. Oncol., 191, e90 Stephenson, 2019, Diagnosis and treatment of early stage testicular cancer: AUA guideline, J.Urol, 202, 272, 10.1097/JU.0000000000000318 Salminen, 2017, Cancer death risk related to radiation exposure from computed tomography scanning among testicular cancer patients, Anticancer Research, 37, 831, 10.21873/anticanres.11385 Hanna, 2003, Long term effects of Cancer Therapy Graeber, 2018